- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00996203
A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.
2018년 2월 28일 업데이트: Hoffmann-La Roche
Local Open-label Multicenter Study to Evaluate the Quality of Life in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to DMARDs When Adding Tocilizumab (TCZ)
This open-label single arm study will evaluate the efficacy and safety of tocilizumab added to traditional disease-modifying antirheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis and an inadequate response to DMARDs.
Patients will receive tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 24 weeks, in addition to their current non-biologic DMARDs at stable doses.
Anticipated time on study treatment is 24 weeks, and the target sample size is 200.
연구 개요
상태
완전한
정황
연구 유형
중재적
등록 (실제)
201
단계
- 4단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Chelyabinsk, 러시아 연방, 454076
- Chelyabinsk Regional Clinical Hospital; Rheumatology
-
Cherkess, 러시아 연방, 369000
- Republican clinical hospital of Karachai-Cherkess; Rheumatologic Department
-
Ekaterinburg, 러시아 연방, 620102
- Municipal Autonomous Institution of Healthcare "City Clinical Hospital #40"
-
Ekaterinburg, 러시아 연방, 620102
- Sverdlovsk Regional Clinical Hospital # 1; Rheumatology Dept
-
Irkutsk, 러시아 연방, 664047
- Irkutsk Regional Consulting and Diagnostic Clinical Center; Regional Center of Reumatolodic Deasise
-
Izhevsk, 러시아 연방, 426009
- Republican Clinicodiagnostic Center
-
Kaliningrad, 러시아 연방, 236016
- Kaliningrad Regional Clinical Hospital; Rheumatologic Department
-
Kemerovo, 러시아 연방, 650099
- War Veterans Regional Clinical Hospital;Therapy Department
-
Kirov, 러시아 연방, 610028
- Kirov Regional Clinical Hospital; Reumatology Department
-
Krasnodar, 러시아 연방, 350086
- GUZ Regional clinical hospital # 1
-
Kursk, 러시아 연방, 305007
- GMU Kursk regional clinical hospital
-
Moscow, 러시아 연방, 123060
- Head Clinical Hospital of Internal Affair Ministry of Russia
-
Moscow, 러시아 연방, 129110
- Vladimirskiy Regional Scientific Research Inst.
-
Moscow, 러시아 연방, 115522
- FSBI "Scientific Research Institute of Rheumatology" of russian Academy of Medical Sciences
-
Moscow, 러시아 연방, 115682
- FSBI "FSCC of particularized sorts of medical care and medical technologies of FMBA"
-
Moscow, 러시아 연방, 121359
- FGU Central Clinical Hospital with Polyclinic Administration President RF
-
Nizhny Novgorod, 러시아 연방, 603126
- SIH Nizhny Novgorod Regional Clinical Hospital n.a. Semashko
-
Petrozavodsk, 러시아 연방, 185019
- Republican Hospital named after V.A. Baranov
-
Rostov-na-Donu, 러시아 연방, 344022
- Rostov State Medical University; Cardiorheumatology Department
-
Smolensk, 러시아 연방, 214001
- Clinical hospital #1
-
Surgut, 러시아 연방, 628408
- Surgut Region Clinical Hospital
-
Tjumen, 러시아 연방, 625023
- Glpu Tjumen Regional Clinical Hospital #1
-
UFA, 러시아 연방, 450005
- Republican clinical hospital named after G.G. Kuvatov
-
Ulyanovsk, 러시아 연방, 432063
- State Institution of Healthcare Ulyanovsk Regional Clinical Hospital
-
Veliky Novgorod, 러시아 연방, 173008
- GUZ "Novgorod Regional Clinical Hospital"; Cardioreumatological
-
Voronezh, 러시아 연방, 394066
- Voronezh Regional Clinical Hospital #1
-
Voronezh, 러시아 연방, 394066
- Budget Institution of Healthcare of Voronezh Region "Voronezh Regional Clinical Hospital #1"
-
Yaroslavl, 러시아 연방, 150062
- SHI Yaroslavl Regional Clinical Hospital
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- adult patients, >/= 18 years of age
- moderate to severe active rheumatoid arthritis of >/=6 months duration
- inadequate clinical response to current non-biologic DMARDs
- current DMARDs must be at stable dose for 8 weeks prior to study entry
- oral corticosteroids (</=10mg/day prednisone or equivalent) and NSAIDs must be at stable dose for >/=4 weeks prior to screening
Exclusion Criteria:
- rheumatic autoimmune disease other than RA
- history of or current inflammatory joint disease other than RA
- previous treatment with any biologic DMARD
- functional class IV as defined by the ACR classification
- intra-articular or parenteral corticosteroids within 6 weeks prior to screening
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 1
|
8 mg/kg iv every 4 weeks for 24 weeks
stable doses at investigator's prescription
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Health Assessment Questionnaire (HAQ) Score
기간: Weeks 0, 4, 8, 12, 16, 20, and 24 and Withdrawal Visit
|
HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity.
To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen.
Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all.
Minimum score was 0, maximum score was 3. Withdrawal Visit is the final visit prior to the withdrawal of the subject from the study.
|
Weeks 0, 4, 8, 12, 16, 20, and 24 and Withdrawal Visit
|
|
Percentage of Participants With an HAQ Score Decrease of 20 Percent (%), 50%, and 70% During Tocilizumab Treatment
기간: Weeks 4, 8, 12, 16, 20, and 24
|
HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity.
To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen.
Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all.
Minimum score was 0, maximum score was 3.
|
Weeks 4, 8, 12, 16, 20, and 24
|
|
Change in HAQ Score at Week 24
기간: Baseline and Week 24
|
HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity.
To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen.
Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all.
Minimum score was 0, maximum score was 3.
|
Baseline and Week 24
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pain Score as Assessed by Visual Analogue Scale (VAS)
기간: Weeks 0, 4, 8, 12, 16, 20, and 24
|
Participant's global assessment of pain was assessed using a 100-millimeter (mm) horizontal VAS (0 to 100 mm) with 0=pain absent and 100=intolerable pain.
Participants responded by placing a mark on the line to indicate their current level of pain.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
European Quality of Life - 5 Dimensions (EQ-5D) Score
기간: Weeks 0, 4, 8, 12, 16, 20, and 24
|
EQ-5D questionnaire assess 5 domains of quality of life including mobility, self-care, habitual daily activities, pain, discomfort, and anxiety/depression.
Each of five domains was assessed by 3 levels depending on severity of a problem and scored using the following: 1=no disturbances, 2=moderate disturbances, 3=severe disturbances.
Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Change in EQ-5D Score at Week 24 From Baseline
기간: Baseline and Week 24
|
EQ-5D questionnaire assess 5 domains of quality of life including mobility, self-care, habitual daily activities, pain, discomfort, and anxiety/depression.
Each of five domains was assessed by 3 levels depending on severity of a problem and scored using the following: 1=no disturbances, 2=moderate disturbances, 3=severe disturbances.
Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Minimum clinically significant change in EQ-5D corresponds to the parameter differences before and after treatment = 0.10.
Graduations of assessment of the therapy efficacy by EQ-5D are: Difference (Δ) EQ-5D less than (<)0.10 points: none; 0.10 less than or equal to (≤)Δ EQ-5D ≤0.24: minimal effect; 0.24≤ Δ EQ-5D <0.31: satisfactory effect; Δ EQ-5D greater than or equal to (≥)0.31 points: pronounced effect.
|
Baseline and Week 24
|
|
General Health Score as Assessed by EQ-5D VAS
기간: Weeks 0, 4, 8, 12, 16, 20, and 24
|
Participant-reported general health quality was assessed using an EQ-5D 100-mm horizontal VAS (0 to 100 mm) with 0=worst health state and 100=the best health state.
The participants were asked to mark the line that corresponded to assessment of general health quality.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Percentage of Participants Achieving a Positive Response on Health Quality Assessment of EQ-5D
기간: Weeks 0, 4, 8, 12, 16, 20, and 24
|
Participant-reported general health quality was assessed using an EQ-5D 100-mm horizontal VAS (0 to 100 mm) with 0=worst health state and 100=the best health state.
The participants were asked to mark the line that corresponded to assessment of general health quality.
Positive response was defined as an increase of EQ-5D score by 0.1 or more i.e. it is a clinically significant increase.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Change in General Health Assessed by VAS
기간: Baseline and Week 24
|
Participant-reported general health quality was assessed using an EQ-5D 100-mm horizontal VAS (0 to 100 mm) with 0=worst health state and 100=the best health state.
The participants were asked to mark the line that corresponded to assessment of general health quality.
|
Baseline and Week 24
|
|
Disease Activity Score Based on 28-Joint Count (DAS28)
기간: Weeks 0, 4, 8, 12, 16, 20, and 24
|
DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Change in DAS28 Score From Baseline to Week 24
기간: Baseline and Week 24
|
Baseline and Week 24
|
|
|
Percentage of Patients With Varied Disease Activity Assessed Using DAS28 During Tocilizumab Treatment
기간: Weeks 0, 4, 8, 12, 16, 20, and 24
|
DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR mm/hour, and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity.
Disease activity: 0=remission (DAS28 less than [<] 2.6), I=low (DAS28 less than or equal to [≤]2.6 to <3.2), II=moderate (DAS28=3.2
to 5.1), III=high (DAS28 greater than [>]5.1).
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response
기간: Weeks 0, 4, 8, 12, 16, 20, and 24
|
ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in swollen/tender joint count (66 joints assessed for swelling and 68 joints assessed for tenderness) and in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and acute phase response: C-reactive protein (CRP) or ESR.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
기간: Weeks 4, 8, 12, 16, 20, and 24
|
The DAS28-based EULAR response criteria were used to measure individual response as no effect, good effect, and moderate effect, depending on the extent of change from baseline and the level of disease activity reached.
Good effect: change from baseline >1.2 with DAS28 score ≤3.2; moderate effect: change from baseline >1.2 with DAS28 score 3.2 to 5.1 or change from baseline >0.6 to <1.2 with DAS28 score <3.2; no effect: change from baseline ≤0.6 or change from baseline >0.6 and ≤1.2 with DAS28 score >5.1.
|
Weeks 4, 8, 12, 16, 20, and 24
|
|
C-Reactive Protein
기간: Weeks 4, 8, 12, 16, 20, and 24
|
CRP (milligrams/Liter) is a mediator of inflammation, acute phase protein.
|
Weeks 4, 8, 12, 16, 20, and 24
|
|
Erythrocyte Sedimentation Rate
기간: Weeks 4, 8, 12, 16, 20, and 24
|
ESR (mm/hr) is used to determine the acute phase response.
|
Weeks 4, 8, 12, 16, 20, and 24
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2009년 10월 31일
기본 완료 (실제)
2011년 2월 14일
연구 완료 (실제)
2011년 2월 14일
연구 등록 날짜
최초 제출
2009년 10월 15일
QC 기준을 충족하는 최초 제출
2009년 10월 15일
처음 게시됨 (추정)
2009년 10월 16일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2018년 3월 29일
QC 기준을 충족하는 마지막 업데이트 제출
2018년 2월 28일
마지막으로 확인됨
2018년 2월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .